Galvokimig for COPD with Chronic Bronchitis: 24 to 52 Weeks of Treatment

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 2 interventional trial compares Galvokimig to placebo over 24 to 52 weeks in adults with moderate-to-severe COPD with chronic bronchitis who are on stable inhaled therapy. The primary goal is to see if Galvokimig can delay the first acute exacerbation of COPD. Participants must have a history of frequent exacerbations and adequate inhaler technique, and they will be followed for safety and efficacy outcomes. The study is conducted at three sites in California and Florida under the sponsor UCB Biopharma SRL.

Why it matters

Who can join: the full rules

Inclusion criteria:

* Participant must be aged ≥40 to ≤80 years of age, inclusive, at the time of signing the Informed Consent form (ICF)
* Participant with a documented physician-diagnosed moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD) with chronic bronchitis phenotype
* Participant has a documented record of receiving maintenance inhaled therapy at a stable dose for ≥3 months prior to Screening comprised of:

  • long-acting beta2 agonist (LABA) +long-acting muscarinic antagonist (LAMA) ±inhaled corticosteroid (ICS)
* Participant at a high risk of exacerbations, defined as a documented exacerbation history of ≥2 moderate or severe acute exacerbation(s) of chronic obstructive pulmonary disease (AECOPD) in the 12 months prior to Screening or 1 severe AECOPD in the 6 months prior to Screening
* Participant has a Chronic Airways Assessment Test (CAAT) score of ≥15 at Screening
* Participant has acceptable inhaler and spirometry techniques according to American Thoracic Society/European Respiratory Society (ATS/ERS) guidelines during the Screening Visit
* Participant can be male or female.

  * A male participant must agree to use contraception during the Intervention Periods and for at least 60 days after the final dose of study intervention and refrain from donating sperm during this period
  * A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies:

    * Not a women of childbearing potential (WOCBP) OR
    * A WOCBP who agrees to follow the contraceptive guidance during the Intervention Periods and for at least 60 days after the final dose of study intervention
* Participant is a current or ex-smoker (with tobacco smoking history of ≥10 pack-years)

Exclusion criteria:

* Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
* Participant has a history of uncompensated heart failure, fluid overload, or myocardial infarction, or evidence of new onset ischemic heart disease or in the opinion of the investigator other serious cardiac disease, within 12 months prior to Screening
* Participant has a presence or a family history (first degree) of inflammatory bowel disease (IBD)
* Participant has uncontrolled neuropsychiatric disorder, active suicidal ideation, or positive suicidal behavior
* Participant has a history of chronic or recurrent clinically significant infections, or a serious extrapulmonary infection within the 6 months prior to Baseline
* Participant has clinically important pulmonary disease other than COPD with chronic bronchitis
* Participant has hypercapnia requiring bilevel positive airway pressure (BiPAP)
* Participant has had a live or attenuated vaccines within 4 weeks prior to Screening or plans to receive such vaccines during the study
* Participant has relevant safety events to one or more interleukin (IL)-13 or IL-17 biologic response modifiers that resulted in discontinuation and change of treatment
* Participant has absolute neutrophil count (ANC) \<1.5 × 10³/μL
* Participant has a corrected QT interval (QTc) \>450msec for male participants or QTc \>470msec for female participants or QTc \>480 msec in participants with bundle branch block
* Participant has a history of past or current chronic alcohol or drug abuse within the previous 12 months

Where it's running

• Copd01 50021
  Encino, California, United States Recruiting
• Copd01 50016
  Westminster, California, United States Recruiting
• Copd01 50011
  Miami, Florida, United States Recruiting
• Copd01 50008
  Rincon, Georgia, United States Recruiting
• Copd01 50017
  Charlotte, North Carolina, United States Recruiting
• Copd01 50003
  Columbus, Ohio, United States Recruiting

Study contacts

• Study coordinator: UCB Cares
• Email: ucbcares@ucb.com
• Phone: 1-844-599-2273 (USA)

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Flutter therapy added to chest physiotherapy after CABG in COPD patients

  This study tests whether adding Flutter therapy to standard chest physiotherapy helps post-CABG patients with mild-to-moderate COPD improve breathing more than chest physiotherapy alone.

  Recruiting Foundation University Islamabad · Rawalpindi · NCT07875049

• TPB-based cadence exercise and breathing training for COPD patients

  A TPB-based program tests whether breathing training, cadence-guided walking, or both can improve lung function, exercise capacity, and quality of life in adults with COPD.

  Recruiting Fu Jen Catholic University Hospital · New Taipei City, New Taipei City and 1 other locations · NCT07860008

• See how dynamic chest X-rays relate to COPD patterns and progression risk

  This study looks at existing dynamic chest radiography data to see if new imaging measurements can identify COPD patterns, gauge severity, and predict who may experience faster progression.

  Recruiting Nanfang Hospital, Southern Medical University · Guangzhou, Guangdong · NCT07762573

• Personalized mobile app warnings to reduce COPD flares

  A personalized mobile app tests whether providing temperature-related risk warnings and protective tips, in addition to usual COPD care, can lower COPD flare-ups over 12 months.

  Recruiting at 4 sites Centers for Disease Control and Prevention, China · Beijing and 3 other locations · NCT07656142

• CLEAR model to predict when people with severe COPD can be taken off ventilatory support

  This project will see if the CLEAR model can predict which adults with severe COPD on invasive or non‑invasive ventilation can be safely taken off ventilatory support.

  Recruiting Assiut University · Asyut, Assuit Egypt · NCT07579052

• Long-term safety of Tozorakimab in COPD patients with prior exacerbations

  This study tests two long-term dosing regimens of tozorakimab in people with COPD who have a history of flare-ups and who completed earlier studies.

  Recruiting at 5 sites Phase 3 AstraZeneca · Aix-en-Provence and 12 other locations · NCT07566195

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.